Rituximab Selectively Suppresses Specific Islet Antibodies
OBJECTIVE The TrialNet Study Group evaluated rituximab, a B-cell–depleting monoclonal antibody, for its effect in new-onset patients with type 1A diabetes. Rituximab decreased the loss of C-peptide over the first year of follow-up and markedly depleted B lymphocytes for 6 months after administration. This article analyzes the specific effect of rituximab on multiple islet autoantibodies.
RESEARCH DESIGN AND METHODS A total of 87 patients between the ages of 8 and 40 years received either rituximab or a placebo infusion weekly for four doses close to the onset of diabetes. Autoantibodies to insulin (IAAs), GAD65 (GADAs), insulinoma-associated protein 2 (IA2As), and ZnT8 (ZnT8As) were measured with radioimmunoassays. The primary outcome for this autoantibody analysis was the mean level of autoantibodies during follow-up.
RESULTS Rituximab markedly suppressed IAAs compared with the placebo injection but had a much smaller effect on GADAs, IA2As, and ZnT8As. A total of 40% (19 of 48) of rituximab-treated patients who were IAA positive became IAA negative versus 0 of 29 placebo-treated patients (P < 0.0001). In the subgroup (n = 6) treated within 50 days of diabetes, IAAs were markedly suppressed by rituximab in all patients for 1 year and for four patients as long as 3 years despite continuing insulin therapy. Independent of rituximab treatment, the mean level of IAAs at study entry was markedly lower (P = 0.035) for patients who maintained C-peptide levels during the first year of follow-up in both rituximab-treated and placebo groups.
CONCLUSIONS A single course of rituximab differentially suppresses IAAs, clearly blocking IAAs for >1 year in insulin-treated patients. For the patients receiving insulin for >2 weeks prior to rituximab administration, we cannot assess whether rituximab not only blocks the acquisition of insulin antibodies induced by insulin administration and/or also suppresses preformed insulin autoantibodies. Studies in prediabetic non–insulin-treated patients will likely be needed to evaluate the specific effects of rituximab on levels of IAAs.
Although the anti-CD20 monoclonal antibody rituximab (Rituxan; Genentech, Biogen-IDEC Pharmaceuticals) originally was introduced for therapy of B-cell lymphomas (1), and subsequently applied to a series of antibody-mediated autoimmune disorders, it also has a role in what were thought to be classic T-cell–mediated autoimmune disorders, such as multiple sclerosis (2,3). In several of these diseases, therapeutic responses occur without a change in levels of characteristic autoantibodies. For some immune-mediated disorders, it has been reported that only a subset of autoantibodies decreases following rituximab. For example, it has been reported that rituximab therapy does not decrease the overall thyrotropin receptor–binding antibody, whereas stimulatory thyrotropin receptor–binding antibodies were decreased (4). The etiology of this differential effect is unknown, but it has been hypothesized to relate to the site of autoantibody production, with the observation that although rituximab does not target plasma cells, it does alter tertiary lymphoid structures and short-lived plasma cells that do not reside in the bone marrow (5).
The quantitative effect of rituximab on islet autoantibodies in patients with diabetes has not been described. Type 1A, or immune-mediated, diabetes is believed to result from T-cell–mediated destruction of islet β-cells (6). Although T cells are dominant determinants of β-cell destruction in the NOD mouse, and diabetes has been reported in one child lacking B cells (7), multiple studies document a role for both B lymphocytes and autoantibodies in the NOD mouse model (8–11). For both humans and the NOD mouse, anti-CD20 antibodies suppress disease progression (11,12). The study by Pescovitz et al. (12) documented the preservation of C-peptides relative to placebo patients at the 1-year follow-up (see Supplementary Appendix). In this study, we analyzed the effects of rituximab on islet autoantibody levels in both placebo- and rituximab-treated new-onset patients from this trial, using a fluid-phase radioimmunoassay to detect autoantibodies against multiple islet antigens (autoantibodies to insulin [IAAs], GAD65 [GADAs], insulinoma-associated protein 2 [IA-2; IA2As], and ZnT8 [ZnT8As]).
RESEARCH DESIGN AND METHODS
The details of patient recruitment, protocol, and the effect on primary and secondary metabolic outcomes are published (12), and the patients in this report are identical to those in the report of Pescovitz et al. (12). For this study, participants and/or parents provided written informed consent, and consent documents were approved by independent ethics committees or institutional review boards at each participating center. In brief, a single course of rituximab (375 mg/m2 infusions on days 1, 8, 15, and 22 of the study) versus placebo was administered in a blinded fashion to 87 patients between the ages of 8 and 40 years with type 1 diabetes who had at least one islet autoantibody (IAAs [if within 7 days of starting insulin], GADAs, IA2As, and islet cell antibodies). At follow-up visits of up to 3 years, serum samples were obtained for determination of islet autoantibodies as well as metabolic evaluation with their C-peptide levels. The subjects who had a decrease in C-peptides greater than or equal to the 50th percentile within-subject variation were defined as nonresponders. Subjects who did not meet the nonresponder criterion were classified as responders (i.e., the subjects either had an increase in C-peptides from baseline or had a decrease in C-peptides from baseline but had a within-subject variation of less than the 50th percentile).
Islet autoantibody determination.
Biochemical islet autoantibodies IAAs, GADAs, IA2As, and ZnT8As were measured with radioimmunoassay using the protein A capture and 96-well filtration-plate format. All samples were analyzed in duplicate, and positive results (index higher than the 99th percentile of normal control subjects) were repeated for confirmation. The GADA and IA2A tests were done in a combined radioassay (13), and the IAA test was performed with a competition radioimmunoassay (14). Levels of autoantibodies are expressed as an index (index = CPMsample − CPMnegative control)/(CPMpositive control − CPMnegative control where CPM is counts per minute, with each antibody having its own positive standard for calculations. The interassay coefficients of variation are 10.0% for GADAs, 5.7% for IA2As, 10.4% for ZnT8As, and 16% for IAAs in the low-positive range. The upper limits of normal (0.032 for GADAs, 0.049 for IA2As, 0.020 for ZnT8As, and 0.010 for IAAs) were established as the 99th percentile of 100–200 healthy control subjects. In the most recent 2010 Diabetes Autoantibody Standardization Program Workshop, assay sensitivity and specificity were 84 and 99%, respectively, for GADAs; 66 and 100%, respectively, for IA2As; 64 and 100%, respectively, for ZnT8As; and 56 and 100%, respectively, for IAAs.
The Fisher exact test was used to test for category changes in terms of the positivity of the autoantibodies. The Student t test was used for the comparison of mean levels of autoantibodies (Prism Software). Results were considered significant with a two-sided α <0.05.
Of patients treated with rituximab who were initially IAA positive before the trial, 40% (19 of 48) became negative within the first 12 months after the diagnosis of diabetes (Table 1). In contrast, no placebo patient (0 of 29) became IAA negative (P < 0.001). Rituximab did not significantly influence the percentage of subjects who became negative for GADAs, IA2As, or ZnT8As. In the subgroup of six individuals who were treated within 50 days of diagnosis of diabetes (who received 50 days of insulin therapy), IAAs were markedly suppressed by rituximab in all patients for 1 year and in four patients for as long as 3 years, despite continuing insulin therapy.
Figure 1 illustrates the mean levels of IAAs (Fig. 1A), GADAs (Fig. 1B), IA2As (Fig. 1C), and ZnT8As (Fig. 1D) over time from trial entry. Overall, IAAs did not decrease in placebo-treated patients, whereas the IAA mean level in the rituximab-treated group was suppressed by ~75% at 6 months (P < 0.001), with the suppression continuing for the 12 months of follow-up. As shown in Fig. 2A, the IAA levels of patients treated with rituximab soon after insulin therapy remained low for >1 year (compared with most placebo-treated patients), and nearly one-half of patients did not increase to an index >0.1 with up to 3 years of follow-up. All but one of the placebo-treated patients who entered into the study within 50 days of diabetes onset developed an IAA index >0.5, and most patients rapidly achieved such levels shortly after diagnosis, as expected with a subcutaneous insulin injection. In the same patients, GADAs, IA2As, and ZnT8As were relatively stable after rituximab or placebo injections, independent of rituximab injection.
Study participants were divided into two subgroups, independent of rituximab treatment, on the basis of their C-peptide levels during the follow-up, defined as responders and nonresponders in both rituximab- and placebo-injection groups. The categorization was performed without knowledge of IAA status. Surprisingly, IAA levels were significantly lower (P < 0.05) in subjects defined as responders versus those who were nonresponders at time 0 for both rituximab and placebo groups (Fig. 3A). The level of IAAs was remarkably lower in the placebo group from baseline until the 12-month follow-up, whereas the IAAs in the rituximab-treated group were suppressed after treatment. A significantly lower level (P < 0.05) of IA2As also was observed in responders compared with nonresponders, as shown in Fig. 3C, whereas there were no differences for mean GADAs and ZnT8As between the two groups (Fig. 3B and D). At and beyond 12 months, when insulin antibodies were increasing, there was no correlation between IAA levels and C-peptide.
Type 1A, or autoimmune, diabetes is characterized by the presence of a series of autoantibodies targeting islet molecules, including insulin, GAD65, IA-2, and ZnT8 (15). The initial assay for islet autoantibodies measured cytoplasmic islet cell autoantibodies by indirect immunofluorescence, using frozen sections of human pancreata (16). IAAs are not detected with the islet cell antibody assay, whereas GADAs, IA2As, and ZnT8As can be detected. In addition to the autoantibodies, which were present before the diagnosis of diabetes, almost all patients treated with insulin (including patients with type 2 diabetes) developed high levels (relative to levels of prediabetic and new-onset patients) of insulin antibodies (17). Islet autoantibodies have a number of distinguishing characteristics. IAAs often are (but not always) the first autoantibody to appear in children followed from birth (18), and at onset of diabetes, their levels are inversely related to age of diabetes onset (19,20). GADAs change the least with age of onset. ZnT8As are rapidly lost after diabetes onset (21), and IA2As are very specific, identifying a particularly high diabetes risk of prospectively followed nondiabetic children (22). The molecules insulin and ZnT8 are, to a large extent, limited to islet cells, whereas GAD65 and IA-2 are distributed in multiple neuroendocrine tissues. Given these unique properties for each of the islet autoantibodies, it is perhaps not surprising that rituximab had a differential effect upon the measured antibodies, with the most dramatic suppression of insulin autoantibodies and antibodies.
Rituximab treatment has been reported to blunt primary and secondary antibody responses (23,24). Because patients who entered into this study were treated with insulin prior to determination of IAAs, it is not possible to isolate the effect of rituximab on pre-existing IAAs versus prevention and suppression of insulin antibodies induced by subcutaneous insulin therapy. This highlights the need for standardized assays that would distinguish the two types of antibodies. This may be particularly important given recent findings indicating that levels of IAAs, but not GADAs, and IA2As are inversely correlated with the rate at which prediabetic children progress to diabetes (25).
A number of studies have documented the differential effects of anti-CD20 treatment on different antibodies in both humans and animal models. In general, rituximab therapy does not suppress overall IgG compared with its effect on IgM antibodies (12). IgG levels can remain unaltered, whereas specific pathogenic autoantibodies are markedly suppressed. Specific disease-associated autoantibodies that are produced in sites outside of the bone marrow may be more susceptible to anti-CD20 suppression, and this may relate to the differential effect in the current study upon IAAs (5). There is a large body of evidence in the NOD mouse model that insulin may be a primary autoantigen (26,27). In particular, mutating an antigenic insulin peptide prevents diabetes in NOD mice (27), whereas knockouts of both GAD65 and IA-2 do not influence progression to diabetes (28,29). In addition, a polymorphism of the insulin gene correlated with increased levels of thymic insulin message is associated with decreased type 1A diabetes risk (30–32).
Rituximab is remarkably effective in blocking de novo antibody responses and may be able to suppress both IAAs and insulin antibodies (the latter induced by injections of human insulin). In particular, 40% of patients treated with rituximab in the trial became negative (for variable times) for insulin antibodies/IAAs. Studies prior to, or within several weeks of, insulin therapy, given current insulin autoantibody/antibody assays, are needed to define whether rituximab can specifically suppress IAAs.
A significantly lower level of IAAs was observed, independent of rituximab treatment, in subjects defined as C-peptide responders versus nonresponders, particularly evident even in the placebo group. IA2As at entry also were found to be significantly lower (although not as dramatic a difference compared with IAAs) at entry in the placebo group for responders versus nonresponders, whereas no difference was observed for either GADAs or ZnT8As. The levels of IAAs were remarkably lower in responders compared with nonresponders at time 0 for both rituximab- and placebo-injection groups, which may indicate that the levels of IAAs, independent of rituximab treatment, are likely to be associated with disease prognosis or disease progression in patients with newly diagnosed type 1A diabetes. The relationship between the levels of IAAs and disease progression only has been investigated in the prediabetic period with the presence of anti-islet autoantibodies, but this has not been possible to study after disease onset. Among these biochemically defined islet autoantibodies, IAAs are the only ones in which the level is associated with the time to develop clinical type 1A diabetes among multiple autoantibody-positive prediabetic subjects (all followed to diabetes) in the Diabetes Autoimmunity Study in the Young (DAISY) study (33). Higher IAA levels are associated with faster progression to overt diabetes. Combining this previous study with the present observation, IAA level seems to play a role in the prediction of disease progression, and higher levels of IAAs might indicate more aggressive autoimmune destruction of pancreatic β-cells both before and after clinical onset of diabetes. The IAAs in the current study are presumably a mixed population of naturally occurring IAAs and induced insulin antibodies. It needs to be further explored whether only IAAs or both IAAs and insulin antibodies secondary to injected insulin are associated with disease progression and the potentially therapeutic effect of rituximab.
The sponsor of this trial was the Type 1 Diabetes TrialNet Study Group. TrialNet is a clinical trials network funded by National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute for Child Health and Human Development, and the National Center for Research Resources; the Juvenile Diabetes Research Foundation International; and the American Diabetes Association.
No potential conflicts of interest relevant to this article were reported.
L.Y. researched data and wrote the manuscript. K.H., H.K.-S., P.L.M., and B.B. researched data and reviewed and edited the manuscript. A.P. contributed to discussion and reviewed and edited the manuscript. J.K. researched data and reviewed and edited the manuscript. G.S.E. researched data and wrote the manuscript.
Dr. Pescovitz, who headed the TrialNet Anti-CD20 Study, contributed greatly to the early drafts of the manuscript prior to his untimely death.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0674/-/DC1.
- Received May 18, 2011.
- Accepted July 7, 2011.
- © 2011 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.